Amgen Inc. (BMV:AMGN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 4.12T +41.7% |
| Revenue (ttm) | 665.65B +9.1% |
| Net Income | 152.77B +32.1% |
| EPS | 281.23 +31.6% |
| Shares Out | n/a |
| PE Ratio | 26.98 |
| Forward PE | 17.33 |
| Dividend | 173.27 (2.31%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 1,773 |
| Open | 7,500.01 |
| Previous Close | 7,260.00 |
| Day's Range | 7,500.01 - 7,500.01 |
| 52-Week Range | 5,300.00 - 7,580.50 |
| Beta | 0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Amgen's autoimmune drug succeeds in late-stage trial
Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option f...
Amgen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Quarterly revenue exceeded $10 billion, driven by strong growth across key products and robust pipeline progress. Landmark clinical results and regulatory advances support future growth, while disciplined capital allocation and evolving DTC strategies position the business for long-term success.
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN...
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Amgen Transcript: Wells Fargo 21st Annual Healthcare Conference
Quarterly revenues exceeded $10 billion, driven by strong growth across six key product areas and robust pipeline progress. Landmark clinical results for IMDELLTRA and TEZSPIRE, expanding biosimilar portfolio, and strategic focus on productivity and disciplined investment support a positive long-term outlook.
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m.
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Amgen (AMGN) shares sold off after Novartis (NVS) failed to meet its primary endpoint in phase-3 trials. Diane King Hall offers more insight into the volatile moves in the healthcare space.
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Respo...
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market
AI stocks rise despite the market's inflation worries, but Amgen falls following Swiss drugmaker Novartis' disappointing trial data.
Why Amgen Stock Is Dropping After Swiss Rival's Trial Setback
Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.
UK regulator suspends Amgen's Tavneos for new patients over unreliable data
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Gl...
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports ...
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, c...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Amgen Earnings Call Transcript: Q2 2026
Q2 2026 revenues rose 10% year-over-year to over $10 billion, driven by strong growth across six key product areas, with 22 products posting double-digit sales gains. Guidance for 2026 was raised, reflecting robust execution, expanding pipeline, and continued investment in innovation.
Amgen Earnings release: Q2 2026
Amgen released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Amgen Slides: Q2 2026
Amgen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.